Australia's most trusted
source of pharma news
Posted 12 May 2022 AM
The University of Sydney will lead an international consortium chosen by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a variant-proof Covid vaccine.
The consortium was awarded a $27.7 million grant to establish pre-clinical and clinical proof of concept for a protein subunit vaccine. It will be designed to provide broad protection against all known Covid variants of concern, as well as future variants.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.